How much of a roll can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain in medication adherence and outcomes from partnering with other industry stakeholders and programs around the issue.
Read the full article below.
There’s a simple reason why co-pay accumulators captured the industry’s attention when they rolled out in 2017: Healthcare is too damn expensive and co-pay accelerators, at least in theory, offered a financial workaround.
Read the full article here.
A focus on value-based care and other market drivers have led to the development of trendsetters, entrants and disruptors (TEDs). Precision for Value’s Dr. Oyekan and Jorge Font, discuss the five main archetypes of TEDs.
Read the full article here.
Precision medicine is a potential game-changer and oncology expert Jeremy Schafer offers four ways that he believes precision medicine will change cancer treatment.
Read the full article here.
In a new MedAd News feature article on the influence of value assessments, Precision Xtract’s Jacki Chou and Zac Stillerman provide their insights on the growing influence of ICER, and how manufacturers can be more proactive in shaping favorable assessments of their new treatments.
The FDA has finally released its guidance on biosimilar interchangeability. Radar on Specialty Pharmacy speaks with Ryan Cox, Precision for Value Vice President, Access Experience team on how the new guidelines reduce administrative hurdles and duplicative clinical trials. However, he notes that reimbursement issues may discourage uptake.
With the FDA’s approval of Zolgensma, the industry receives another data point in the pricing strategies for new gene therapies. As reported in Radar on Specialty Pharmacy, the two payment options offered by AveXis, makers of Zolgensma, both follow the movement to value-based purchasing. Larry Blandford, executive vice president of Precision Value and Health, discusses the rationale for and potential issues of these strategies.
Despite recent approval of the first new treatment for depression in years, most patients will still use one of the many generics on the market. As reported in Health Plan Weekly, step therapy and generics-first strategies will continue to prevail. Kellie Rademacher, Vice President, Experience and Access Team, Precision for Value, comments.
Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
HHS wants to eliminate drug rebates in Medicare Part D and Medicaid managed care. But the CBO projects the resulting higher premiums will cost the government dearly. In an AIS Health, Radar on Specialty Pharmacy article, Jeremy Schafer, Precision for Value Senior Vice President, Access Experience, weighs in on the potential impact of the rule, and what that means for its future. (more…)